Pharmacist Medication Insights: Fluciclovine F 18 (Axumin) for Prostate Cancer

Article

Fluciclovine F 18 (Axumin), which is a radioactive diagnostic agent for injection that can be used to detect recurring prostate cancer.

Fluciclovine F 18 (Axumin), a radioactive diagnostic agent for injection that can be used to detect recurring prostate cancer, was approved by the FDA in 2016. If a male patient shows signs of elevated prostate specific antigen (PSA) levels, he may benefit from using Axium for positron emission tomography.

Clinical studies demonstrated that Axumin for imaging prostate cancer in men with high PSA levels following prior treatment was safe and effective. However, since Axumin is a radioactive drug, health care professionals should be careful about minimizing radiation exposure.

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Mayo Clinic oncology pharmacy
Therapy session -- Image credit: pressmaster | stock.adobe.com
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Multiple myeloma awareness -- Image credit: Fauzi | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.